Novaremed AG: Novaremed's Non-opioid Lead Compound, NRD.E1,

NIH, through the Helping to End Addiction Long-term Initiative, to sponsor the Phase 2b SERENDIPITY-1 study, evaluating NRD.E1 in patients with painful diabetic peripheral neuropathy (PDPN)

Related Keywords

United States , Mark Altmeyer , Kostenloser Wertpapierhandel , Eva Tiecke , Isaac Kobrin , Early Phase Pain Investigation Clinical Network , Metys Pharmaceuticals Ag Switzerland , End Addiction Initiative , Novaremed Ltd Israel , National Institutes Of Health , Us National Institutes Of Health , End Addiction Long Term Initiative , National Institutes , Executive Chairman , Chief Scientific Officer , Fast Track Designation , Painful Diabetic Peripheral Neuropathy , Randomised Proof , Concept Study , European Journal , Track Designation , Metys Pharmaceuticals , Executive Member , Novaremed , Opioid , Head , Compound , Tested , Meal , Initiative , Hase , Trial , Treatment , Hronic , Rain ,